In patients with atrial fibrillation who were unable to receive warfarin for any reason, the use of apixaban reduced the risk of stroke and systemic embolism when compared to aspirin. Study Rundown: Atrial fibrillation is a common arrhythmia that increases the risk of stroke and. AVERROES has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety. AVERROES. Apixaban Versus ASA. To Reduce the Risk Of Stroke. Coordinated by Population Health Research institute. Hamilton, Ontario, Canada. Sponsors.

Author: Mahn Kekree
Country: Brunei Darussalam
Language: English (Spanish)
Genre: Video
Published (Last): 10 July 2010
Pages: 414
PDF File Size: 15.50 Mb
ePub File Size: 18.23 Mb
ISBN: 984-2-12059-391-8
Downloads: 15189
Price: Free* [*Free Regsitration Required]
Uploader: Nazragore

The AVERROES Trial – Clinical Implications

Of the patients enrolled, reasons for being deemed unsuitable for VKA therapy included the following: VKA therapy not recommended by the physician; Analyses are to time of first event. J Am Coll Cardiol ; Notes to editor Correspondence: All these reasons can be grouped in three broad categories: In addition, patients could not be receiving VKA therapy, either because it had been demonstrated unsuitable in their case or because it was expected to be unsuitable. Concurrent medications whose metabolism could be affected by VKAs; 9.


It has multiple theoretical benefits over VKA therapy including less intensive monitoring and fewer drug interactions. With a mean follow-up of 1. Don’t miss out Read your latest personalised notifications Ok, got it. The New England Journal of Medicine.

AVERROES – Wiki Journal Club

Its role in prevention of stroke in patients unsuitable for VKA therapy, but maintained on aspirin therapy, was unknown. Patients also needed to have at least one of the following risk factors for stroke: Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

Navigation menu Personal tools Create account Log in.

Presented as apixaban vs. Expected difficulty in contacting patient for urgent change in dose of VKAs; 6. ESC sub specialties communities. Apixaabn reduce the burden of cardiovascular disease.

There were 44 1. Did you know that your browser is out of date?

Retrieved from ” http: Apixaban in Patients with Atrial Fibrillation. One may question each of these choices: Views Read View source View history. This page was last modified on 3 Decemberat Sign in to My ESC. Apixaban is a novel oral anticoagulant that inhibits factor Xa.

This proportion was similar for averoes academic and community hospitals. AVERROES on the other hand has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety.


The AVERROES Trial – Clinical Implications

Eur Heart J ; Dual therapy decreased rates of major vascular events at cost of increased major bleeding. To get the best experience using our website we recommend that you upgrade to a newer version. Usable articles Cardiology Neurology. Strengths Strong points and important messages of the study are: The trial was terminated early given a treatment benefit with apixaban. There were 51 primary outcome events in those randomised to apixaban 1.

The primary outcome was stroke or systemic embolism. Patients were eligible if they were 50 years of age or older apjxaban if they had atrial fibrillation that had been documented in the 6 months prior to enrollment or by lead electrocardiography on the day of screening.

Assessment that INR could not or was unlikely to be measured at requested interval; 5.